- Marker Therapeutics reports a 78% objective response rate in Phase 1 APOLLO study for MT-601.
- Lymphodepletion enhances MAR-T cell expansion and persistence in lymphoma patients.
- Record patient enrollment expected to boost clinical data readout in summer 2025.
Marker Therapeutics, Inc. (MRKR, Financial), a clinical-stage immuno-oncology company, has announced encouraging results from its Phase 1 APOLLO study evaluating the efficacy of MT-601, a multi-antigen recognizing (MAR) T cell therapy, in patients with lymphoma. The study highlights the positive impact of lymphodepletion on the expansion and persistence of MAR-T cells, crucial for enhancing anti-tumor activity.
The APOLLO study reported a 78% objective response rate, with seven out of nine patients showing significant improvement. Furthermore, 44.4% of the participants achieved a complete response within just four weeks of treatment with MT-601. Importantly, no dose-limiting toxicities or incidents of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed, affirming an excellent safety profile for the therapy.
Early 2025 saw Marker Therapeutics achieve its highest-ever patient enrollment rate, with more participants signed up within the first five months than throughout the whole of 2024. This rapid increase in enrollment indicates strong interest from both physicians and patients and points to robust clinical trial outcomes.
Marker Therapeutics plans to release comprehensive data from the APOLLO study in summer 2025, providing more insights into the long-term benefits and durability of the MAR-T cell therapy. The company's strategic focus on lymphodepletion is seen as a critical advancement in improving clinical results and ensuring sustained therapeutic benefits against lymphoma.
